Ataluren, formerly known as PTC124, is a small-molecular agent designed by PTC Therapeutics and sold under the trade name Translarna in the European Union.
Ataluren, formerly known as PTC124, is a pharmaceutical drug for the treatment of Duchenne muscular dystrophy and potentially other genetic disorders. It was designed by PTC Therapeutics and is sold under the trade name Translarna in the European Union.